Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025)

Artiva Biotherapeutics (ARTV) posted quarterly Capital Leases of $11000.0 for Q1 2025, down 75.0% quarter-over-quarter from $44000.0 in Q4 2024.

Analysis

Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025) Analysis & Trends

Artiva Biotherapeutics (ARTV) has reported Capital Leases for 2 consecutive years, with $11000.0 the latest figure, recorded in Q1 2025.

In Q1 2025, Capital Leases changed N/A year-over-year to $11000.0; the TTM figure through Mar 2025 stood at $11000.0 (changed N/A YoY), while the FY2024 annual figure was $44000.0, changed N/A from the prior year.
Capital Leases declined to $11000.0 in Q1 2025 per ARTV's latest filing, from $44000.0 in the prior quarter.
Across five years, Capital Leases topped out at $106000.0 in Q2 2024 and bottomed at $11000.0 in Q1 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Artiva Biotherapeutics	441.23 Mn	441.23 Mn	-

Historic Data

Download Data